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Aim: To investigate the effect of chronic-moderate ethanol (CME) treatment upon direct 
activation and allosteric modulation of GABAA receptors, and to assess the sensitivity of 
these parameters to PKC inhibition in control and ethanol-treated cells. 
Methods: L(tk-) cells were exposed to 20mM ethanol in culture media for 14 days prior to 
induction of stable expression of human recombinant α4β3δ receptors using dexamethasone. 
Concentration-response curves for GABA (1nM - 100µM), and allopregnanolone (ALLO; 
1nM - 30µM) co-applied with 200nM GABA were obtained using whole-cell patch-clamp 
electrophysiology at a holding voltage of -60 mV. 400nM calphostin C (CphC) or vehicle 
(DMSO) was administered to cells via the pipette solution, which was prepared with 2mM 
Mg.ATP. SDS-PAGE and western blotting were used to compare levels of whole-cell 
expression, quantified relative to β-actin, of α4 and δ GABAA receptor subunits, and several 
isoforms of PKC (α, γ, δ, and ε), in control and CME-treated cells. Data was reported as Mean 
± SEM and significance determined by either one-way ANOVA with Newman-Keuls 
multiple comparison tests, or two-way, unpaired t-tests. 
Results: Expression of α4 subunits was reduced 35% (P<0.05) in ethanol-treated cells but the 
efficacy (control: 9.04±0.93 pA/pF, n=41, CME: 6.39±1.16 pA/pF, n=13, P>0.05) and pEC50 
(control: 6.18±0.04, n=13, CME: 6.17±0.04, n=4, P>0.05) of GABA were unchanged. CphC 
increased the GABA pEC50 relative to control (6.62±0.08, n=3, P<0.001) but had no effect 
upon responses at pEC20 GABA. Following CME, the potency of GABA was unaltered in the 
presence of CphC. 
The magnitude of ALLO-induced potentiation in control cells (7.34±0.6 fold, n=19) was 
unchanged by CME (ATP: 7.39±1.0 fold, n=9, P>0.05), and CphC had no significant effect in 
control or CME-treated cells. 
The ALLO pEC50 in control cells (6.23±0.05, n=19) was unaffected by CphC. Following 
CME, the potency of ALLO was reduced (5.68±0.06, n=9, P<0.001) but was enhanced in the 
presence of CphC, which restored potency almost back to control levels (5.94±0.09, n=5, 
P<0.05 relative to control). 
Expression of the α, γ, δ, and ε isoforms of PKC was detected in whole-cell lysates of L(tk-) 
cells but only PKCα was significantly altered by CME treatment, exhibiting a nearly 4-fold 
increase (3.9±0.47 fold P<0.01) when compared with that in controls. 
Discussion: CME of un-induced L(tk-) cells was sufficient to alter sensitivity of α4β3δ 
receptor function to alterations of the balance of phosphorylation induced by CphC. The 
increased expression of PKCα after CME may have been directly related to the absence of 
effect of CphC upon GABA potency. As direct interaction of GABAA receptors with PKCα 
has not been determined, the effects observed for potency and efficacy of ALLO following 
CME may be indicative of changes to the phosphorylation of accessory proteins or other PKC 
isoforms by PKCα. 
